- You are here: Home |
- CML Advocates Network - advocates
advocatesChronic Myeloid Leukemia
also called: Chronic Myelogeneous Leukemia
A chronic disease of the blood and bone marrow that results from a transformation of a stem cell.
BCR-ABL ratio
The BCR-ABL ratio is a quantitative determination of the CML-typical BCR-ABL gen. The number of BCR-ABL “copies” in relation to a control gen which is present in all cells is a measure of disease activity or "tumour burden" of CML. In lab reports, this value is frequently stated in percent, but sometimes also as a "ratio" or "quotient". In general, the control gen "ABL" is used to calculate the quotient, but other genes may also be used (e.g. BCR, GUSB, G6PD).
Hematologist
A physician who has specialized in blood diseases, including leukemia ("heme" means "blood" in Greek language)
Compliance
Willingness of a patient to reliably adhere to treatment measures and follow medical instructions.
Generics
A class of medicinal products where the drug is comparable to a branded product in dosage form, strength, route of administration, quality and efficacy, and intended use. A generic drug can only be marketed after patent exclusivity protection ends.
Imatinib
Imatinib, trade name Glivec/Gleevec, development name STI-571, a first-generation BCR-ABL tyrosine kinase inhibition. Authorized for marketing since 2002 for the treatment of CML and Ph-positive ALL.
Other names: Gleevec|Glivec
COVID-19
(Also called Coronavirus or SARS-Cov 2) An infectious disease caused by a newly discovered coronavirus in 2019. Most people infected with the COVID-19 virus experience mild to moderate respiratory illness and recover without requiring special treatment. Older people and those with underlying medical problems like cardiovascular disease, diabetes, chronic respiratory disease, and cancer, are more likely to develop serious illness.
BCR-ABL
The abnormal gene that characterizes Chronic Myeloid Leukemia, which is a fusion of the BCR gene of chromosome 9 and the ABL gene of chromosome 22
Chronic
Long-lasting, slowly developping
Acute
Of sudden onset, severe; of short duration.
CLL
Chronic lymphocytic leukemia
Gene
A unit of information present as DNA; a gene usually contains the blueprint for a protein.
CML
Chronic Myeloid Leukemia, also called Chronic Myelogenous Leukemia
A chronic disease of the blood and bone marrow that results from a transformation of a stem cell.
ASH
American Society of Hematology
MR4
Molecular response, or molecular remission, with a reduction of 4 log (BCR-ABL <0,01%)
CHR
Abbreviation for Complete Hematologic Response. The blood cell count has returned to normal, and tests don’t show any immature white blood cells. Also, the spleen has returned to a normal size if it was enlarged.
TFR
Abbreviation for Treatment-Free Remission. In CML is referred to having a stable deep molecular response without the need for ongoing Tyrosine Kinase Inhibitor (TKI) treatment after having been in deep molecular residual disease over a longer period of time.
Chronic Myeloid Leukemia
also called: Chronic Myelogeneous Leukemia
A chronic disease of the blood and bone marrow that results from a transformation of a stem cell.
BCR-ABL ratio
The BCR-ABL ratio is a quantitative determination of the CML-typical BCR-ABL gen. The number of BCR-ABL “copies” in relation to a control gen which is present in all cells is a measure of disease activity or "tumour burden" of CML. In lab reports, this value is frequently stated in percent, but sometimes also as a "ratio" or "quotient". In general, the control gen "ABL" is used to calculate the quotient, but other genes may also be used (e.g. BCR, GUSB, G6PD).
Hematologist
A physician who has specialized in blood diseases, including leukemia ("heme" means "blood" in Greek language)
Compliance
Willingness of a patient to reliably adhere to treatment measures and follow medical instructions.
Generics
A class of medicinal products where the drug is comparable to a branded product in dosage form, strength, route of administration, quality and efficacy, and intended use. A generic drug can only be marketed after patent exclusivity protection ends.
Imatinib
Imatinib, trade name Glivec/Gleevec, development name STI-571, a first-generation BCR-ABL tyrosine kinase inhibition. Authorized for marketing since 2002 for the treatment of CML and Ph-positive ALL.
Other names: Gleevec|Glivec
COVID-19
(Also called Coronavirus or SARS-Cov 2) An infectious disease caused by a newly discovered coronavirus in 2019. Most people infected with the COVID-19 virus experience mild to moderate respiratory illness and recover without requiring special treatment. Older people and those with underlying medical problems like cardiovascular disease, diabetes, chronic respiratory disease, and cancer, are more likely to develop serious illness.
BCR-ABL
The abnormal gene that characterizes Chronic Myeloid Leukemia, which is a fusion of the BCR gene of chromosome 9 and the ABL gene of chromosome 22
Chronic
Long-lasting, slowly developping
Acute
Of sudden onset, severe; of short duration.
CLL
Chronic lymphocytic leukemia
Gene
A unit of information present as DNA; a gene usually contains the blueprint for a protein.
CML
Chronic Myeloid Leukemia, also called Chronic Myelogenous Leukemia
A chronic disease of the blood and bone marrow that results from a transformation of a stem cell.
ASH
American Society of Hematology
MR4
Molecular response, or molecular remission, with a reduction of 4 log (BCR-ABL <0,01%)
CHR
Abbreviation for Complete Hematologic Response. The blood cell count has returned to normal, and tests don’t show any immature white blood cells. Also, the spleen has returned to a normal size if it was enlarged.
TFR
Abbreviation for Treatment-Free Remission. In CML is referred to having a stable deep molecular response without the need for ongoing Tyrosine Kinase Inhibitor (TKI) treatment after having been in deep molecular residual disease over a longer period of time.
EU e-Privacy Directive
EU e-Privacy Directive
This website uses cookies to manage authentication, navigation, and other functions. By using our website, you agree that we can place these types of cookies on your device.
You have declined cookies. This decision can be reversed.
You have allowed cookies to be placed on your computer. This decision can be reversed.